Cor Vasa 2007, 49(6):222-224 | DOI: 10.33678/cor.2007.080

Combination therapy using inhaled iloprost and sildenafil in a patient with idiopathic pulmonary arterial hypertension

Hikmet Al-Hiti*, Jiří Kettner, Jiří Widimský, Josef Kautzner
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

The authors provide a brief overview of the therapeutic options in idiopathic pulmonary arterial hypertension (IPAH), and present the case report of a patient with moderate IPAH, in whom the above therapeutic strategy was employed for the first time in the Czech Republic.

Keywords: Idiopathic pulmonary arterial hypertension; Pulmonary arterial hypertension; Combination therapy

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Al-Hiti H, Kettner J, Widimský J, Kautzner J. Combination therapy using inhaled iloprost and sildenafil in a patient with idiopathic pulmonary arterial hypertension. Cor Vasa. 2007;49(6):222-224. doi: 10.33678/cor.2007.080.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-78.
    2. Rich S, Kaufmann E, Levy PS. The effect of high doses of kalcium channel blockers on survival in primary pulmonary hypertension. New Engl J Med 1992;327: 76-81. Go to original source... Go to PubMed...
    3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group (see comments). New Engl J Med 1996; 334:296-302. Go to original source... Go to PubMed...
    4. Higenbottam T. Treatment of pulmonary hypertension by inhaled delivery. Prague: The Parthenon Publishing Group, 1999:9-17.
    5. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Rur J Clin Pharmacol 1986;30:61-8. Go to original source... Go to PubMed...
    6. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000;35:176-182. Go to original source... Go to PubMed...
    7. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. New Engl J Med 2002;347:322-9. Go to original source... Go to PubMed...
    8. Hoeper MM, Schwarze M, Ehlerging S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New Engl J Med 2000; 347:1866-70. Go to original source... Go to PubMed...
    9. Prasat S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. New Engl J Med 2000;343:1342-3. Go to original source... Go to PubMed...
    10. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patient with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207-13. Go to original source... Go to PubMed...
    11. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil and safe and improves functional capacity and hemodynamics in patient with pulmonary arterial hypertension. Circulation 2003;108: 2006-69. Go to original source... Go to PubMed...
    12. Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical effcacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53. Go to original source... Go to PubMed...
    13. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005;353:2148-57. Go to original source... Go to PubMed...
    14. Yanagisawa M. The endotelin system. A new target for therapeutic intervention. Circulation 1994;89:1320-2. Go to original source... Go to PubMed...
    15. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346:869-903. Go to original source... Go to PubMed...
    16. Langleben D, Brock T, Dixon R, Barst R. STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials. J Cardiovasc Pharmacol 2004;44: S80-S84. Go to original source... Go to PubMed...
    17. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970;2:92-8. Go to original source...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes